IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. | IGM Biosciences ended last year ...

Antibiotics are one of the most common medicines in the world, with about 236 million prescriptions in the U.S. | The company ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

After a six-month beta testing period, the European Clinical Trials Information Network is rolling out its patient ...

Remedee Labs, a startup based in Paris, France, has received a European approval for its device-based approach to treating ...

Kezar Life Sciences went all in on its autoimmune candidate zetomipzomib after a restructuring last year. | The voluntary ...

Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.

A large trial of people with earlier stages of prostate cancer compared two types of external radiation treatments ...

BridgeBio Pharma has been on the road to redemption ever since its treatment for a rare and fatal heart condition, acoramidis ...

Cereno Scientific’s hypertension drug was shown to improve the risk score of 43% of patients in a phase 2 study.

A bipolar disorder research initiative backed by Big Tech has announced $36 million in new funding for research into the ...

Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that ...